标题
Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
作者
关键词
-
出版物
Cancers
Volume 13, Issue 21, Pages 5471
出版商
MDPI AG
发表日期
2021-11-01
DOI
10.3390/cancers13215471
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era
- (2021) Michael Hwang et al. LANCET ONCOLOGY
- Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
- (2021) Alan L. Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
- (2021) Robert E. Sobol et al. Frontiers in Oncology
- The DNA damage response network in the treatment of head and neck squamous cell carcinoma
- (2021) A. Psyrri et al. ESMO Open
- Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma
- (2021) Ikko Mito et al. Scientific Reports
- Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma
- (2021) Farzaneh Kordbacheh et al. Cancers
- Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR
- (2021) Edyta M. Borkowska et al. Biomolecules
- ERK/MAPK signalling pathway and tumorigenesis (Review)
- (2020) Yan‑Jun Guo et al. Experimental and Therapeutic Medicine
- Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis
- (2020) Aggarwal et al. Vaccines
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC
- (2020) Chao Rong et al. BRITISH JOURNAL OF CANCER
- Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
- (2020) Zi Mei et al. International Journal of Oral Science
- Combination therapy using human papillomavirus L1/E6/E7 genes and archaeosome: a nanovaccine confer immuneadjuvanting effects to fight cervical cancer
- (2020) Hesam Karimi et al. Scientific Reports
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
- (2020) Hoi-Lam Ngan et al. npj Genomic Medicine
- Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
- (2020) Warner K. Huh et al. GYNECOLOGIC ONCOLOGY
- Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
- (2020) Mara Gilardi et al. MOLECULAR CANCER THERAPEUTICS
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
- (2020) Iris Y Sheng et al. Cancer Management and Research
- The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
- (2020) Wen-Qi Cai et al. Frontiers in Oncology
- Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
- (2020) Markus Hecht et al. BMC CANCER
- STAT3 Inhibitor OPB-51602 Is Cytotoxic to Tumor Cells Through Inhibition of Complex I and ROS Induction
- (2020) Lara Brambilla et al. iScience
- A PHASE II STUDY OF PX-866 IN PATIENTS WITH RECURRENT OR METASTATIC CASTRATION RESISTANT PROSTATE CANCER: CANADIAN CANCER TRIALS GROUP STUDY IND205
- (2019) Sebastien J. Hotte et al. Clinical Genitourinary Cancer
- Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
- (2019) Jens von der Grün et al. Cancers
- Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death
- (2019) Anne M. van Harten et al. Oncogenesis
- Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer
- (2019) Michael Xiang et al. Journal of the National Comprehensive Cancer Network
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
- (2019) Joris B.W. Elbers et al. RADIOTHERAPY AND ONCOLOGY
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- (2019) Anna F. Farago et al. Cancer Discovery
- Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
- (2019) Jesús García-Foncillas et al. Frontiers in Oncology
- Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108)
- (2019) K. Klinghammer et al. EUROPEAN JOURNAL OF CANCER
- Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
- (2019) Valerie Cristina et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
- (2019) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
- (2019) Paiyun Li et al. PLoS One
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- (2019) Farzan Solimani et al. Frontiers in Immunology
- Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
- (2018) M Tahara et al. ANNALS OF ONCOLOGY
- Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial
- (2018) Kathryn A. Gold et al. CANCER
- Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
- (2018) Sana D. Karam et al. CLINICAL CANCER RESEARCH
- The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic
- (2018) Wei-Wei Zhang et al. HUMAN GENE THERAPY
- Precision Therapy of Head and Neck Squamous Cell Carcinoma
- (2018) P.J. Polverini et al. JOURNAL OF DENTAL RESEARCH
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- (2018) Matthew H. Bailey et al. CELL
- A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
- (2018) Jordi Rodon et al. Oncotarget
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- The FDA Oncology Center of Excellence and precision medicine
- (2017) Kirsten B Goldberg et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
- (2017) Ramon Salazar et al. ONCOLOGIST
- Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
- (2017) Marco Siano et al. ONCOLOGIST
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma
- (2017) Lillian L. Siu et al. JAMA Oncology
- A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
- (2017) S. Verstovsek et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
- (2017) N. W. Choong et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma
- (2016) Jared M. Weiss et al. CANCER
- HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
- (2016) Xavier Castellsagué et al. JNCI-Journal of the National Cancer Institute
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
- (2016) Sohita Dhillon Targeted Oncology
- HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
- (2016) Xavier Castellsagué et al. JNCI-Journal of the National Cancer Institute
- Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion
- (2016) Rong Biaoxue et al. Scientific Reports
- Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
- (2015) E. Massarelli et al. ANNALS OF ONCOLOGY
- A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer
- (2015) Paul L. Swiecicki et al. INVESTIGATIONAL NEW DRUGS
- Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- (2015) Kevin Harrington et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
- (2015) Jill Gilbert et al. ORAL ONCOLOGY
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
- (2015) Patcharee Ritprajak et al. ORAL ONCOLOGY
- Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial
- (2014) Yi Li et al. BMC Medicine
- Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck
- (2014) Nabil F. Saba et al. CANCER
- Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933
- (2014) Sylvia M. Lee et al. CANCER
- An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
- (2014) Vassiliki Saloura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Erlotinib, Erlotinib-Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
- (2014) N. D. Gross et al. CLINICAL CANCER RESEARCH
- RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
- (2014) T. Rampias et al. CLINICAL CANCER RESEARCH
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer
- (2014) Fredrik Jerhammar et al. ORAL ONCOLOGY
- STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma
- (2014) Jonah D. Klein et al. PLoS One
- Characterization of HPV and host genome interactions in primary head and neck cancers
- (2014) M. Parfenov et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical update on cancer: molecular oncology of head and neck cancer
- (2014) Y Suh et al. Cell Death & Disease
- A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
- (2013) S Sahebjam et al. BRITISH JOURNAL OF CANCER
- A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer
- (2013) A. Eustace et al. CLINICAL CANCER RESEARCH
- Head and Neck Tumor Hypoxia Imaging by 18F-Fluoroazomycin-arabinoside (18F-FAZA)-PET
- (2013) Gyorgy B. Halmos et al. CLINICAL NUCLEAR MEDICINE
- Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinomain situ
- (2013) Hitchintan Kaur et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
- (2013) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
- (2013) Renato G. Martins et al. JOURNAL OF CLINICAL ONCOLOGY
- HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
- (2013) Mariette I E van Poelgeest et al. Journal of Translational Medicine
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines
- (2013) Hanneke Stegeman et al. Molecular Cancer
- Cancer genome-sequencing study design
- (2013) Jill C. Mwenifumbo et al. NATURE REVIEWS GENETICS
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
- (2013) Sewanti Limaye et al. ORAL ONCOLOGY
- A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
- (2013) Julie E. Bauman et al. ORAL ONCOLOGY
- The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer
- (2013) J-L Roh et al. Cell Death & Disease
- Expression and significance of hypoxia-inducible factor-1α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells
- (2013) JIN XIE et al. Oncology Letters
- A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
- (2013) F Hayakawa et al. Blood Cancer Journal
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
- (2012) A. Argiris et al. ANNALS OF ONCOLOGY
- A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
- (2012) Matthew G. Fury et al. CANCER
- The Genetic Basis for Cancer Treatment Decisions
- (2012) Janet E. Dancey et al. CELL
- A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2012) J. A. de Souza et al. CLINICAL CANCER RESEARCH
- Next-generation sequencing in breast cancer
- (2012) Christine Desmedt et al. CURRENT OPINION IN ONCOLOGY
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
- (2012) Libero Santarpia et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- An emerging toolkit for targeted cancer therapies
- (2012) G. B. Mills GENOME RESEARCH
- Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma
- (2012) Jonah D. Klein et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET
- (2012) Jeffrey R. Infante et al. INVESTIGATIONAL NEW DRUGS
- Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
- (2012) Tanguy Seiwert et al. INVESTIGATIONAL NEW DRUGS
- Successful hyperbaric oxygen therapy for laryngeal radionecrosis after chemoradiotherapy for mesopharyngeal cancer: case report and literature review
- (2012) Madoka Abe et al. JAPANESE JOURNAL OF RADIOLOGY
- Molecular genetics of head and neck cancer (Review)
- (2012) Shitij Arora Molecular Medicine Reports
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- Hypoxia Gene Expression Signatures as Prognostic and Predictive Markers in Head and Neck Radiotherapy
- (2012) Kasper Toustrup et al. SEMINARS IN RADIATION ONCOLOGY
- Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
- (2011) T. C. Gauler et al. ANNALS OF ONCOLOGY
- Unraveling the Genetics of Cancer: Genome Sequencing and Beyond
- (2011) Kit Man Wong et al. Annual Review of Genomics and Human Genetics
- Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
- (2011) N B Leighl et al. BRITISH JOURNAL OF CANCER
- Development of a Hypoxia Gene Expression Classifier with Predictive Impact for Hypoxic Modification of Radiotherapy in Head and Neck Cancer
- (2011) K. Toustrup et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro
- (2011) D. Sano et al. CLINICAL CANCER RESEARCH
- Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab
- (2011) Chulso Moon et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
- (2011) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
- (2011) Jean-Pascal Machiels et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy
- (2011) C. Pinto et al. ONCOLOGIST
- Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
- (2010) R. Mesía et al. ANNALS OF ONCOLOGY
- The role of human papillomavirus infection in head and neck cancers
- (2010) S. Syrjanen ANNALS OF ONCOLOGY
- The role of human papillomavirus in head and neck cancer
- (2010) CHRISTEL BRAEMER LAJER et al. APMIS
- Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer
- (2010) M. Tahara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Evolution of the cancer genome
- (2010) Michael R. Stratton CANCER GENETICS AND CYTOGENETICS
- CETUXIMAB: From Bench to Bedside
- (2010) B. Vincenzi et al. CURRENT CANCER DRUG TARGETS
- Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches
- (2010) Stephen Y. Lai et al. DRUG RESISTANCE UPDATES
- Emerging drugs to treat squamous cell carcinomas of the head and neck
- (2010) Christopher Fung et al. EXPERT OPINION ON EMERGING DRUGS
- EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
- (2010) Christian Freudlsperger et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer
- (2010) A Wu et al. GENE THERAPY
- Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420
- (2010) Stephen K. Williamson et al. JOURNAL OF CLINICAL ONCOLOGY
- Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group
- (2010) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Pathway as a Therapeutic Target
- (2010) Eric S. Kim et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- International network of cancer genome projects
- (2010) Thomas J. Hudson (Chairperson) et al. NATURE
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
- (2010) V. E. Kwitkowski et al. ONCOLOGIST
- Mild Hypoxia Enhances Proliferation and Multipotency of Human Neural Stem Cells
- (2010) Guido Santilli et al. PLoS One
- p53-based Cancer Therapy
- (2010) D. P. Lane et al. Cold Spring Harbor Perspectives in Biology
- Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
- (2009) J. Nemunaitis et al. CLINICAL CANCER RESEARCH
- MANAGEMENT OF SKIN RASH DURING EGFR-TARGETED MONOCLONAL ANTIBODY TREATMENT FOR GASTRO INTESTINAL MALIGNANCIES: CANADIAN RECOMMENDATIONS
- (2009) Barb Melosky et al. Current Oncology
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
- (2009) Gini F. Fleming et al. GYNECOLOGIC ONCOLOGY
- Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
- (2009) J. Simon W. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
- (2009) Jean-Pascal H. Machiels et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of PTK/ZK on the Angiogenic Switch in Head and Neck Tumors
- (2009) M. Miyazawa et al. JOURNAL OF DENTAL RESEARCH
- Innovations in Radiotherapy Planning of Head and Neck Cancers: Role of PET
- (2009) E. G.C. Troost et al. JOURNAL OF NUCLEAR MEDICINE
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- (2009) Ezra EW Cohen et al. LANCET ONCOLOGY
- A comprehensive catalogue of somatic mutations from a human cancer genome
- (2009) Erin D. Pleasance et al. NATURE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
- (2008) Rodney J. Taylor et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism
- (2008) P. Mahy et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Therapeutic human papillomavirus vaccines: current clinical trials and future directions
- (2008) Chien-Fu Hung et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab
- (2007) Fernando Rivera et al. ACTA ONCOLOGICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now